-- Scott Roberts
MONDAY, Nov. 11 (HealthDay News) -- Aptiom (eslicarbazepine
acetate) has been approved by the U.S. Food and Drug Administration
as an add-on drug to help treat adults with partial epileptic
Epilepsy, caused by abnormal activity in the brain's nerve
cells, is diagnosed in some 200,000 people annually in the United
States, the agency said in a news release. So-called "partial"
seizures are the most common type of seizure among people with
epilepsy, triggering possible symptoms including repetitive
movement of limbs, unusual behavior and convulsions.
Aptiom's safety and effectiveness were evaluated in three
clinical studies. The most common side effects noted were
dizziness, drowsiness, nausea, headache, double vision and loss of
As with other anti-epileptic drugs, Aptiom may trigger thoughts
of suicide in a small number of users, the FDA said. People who
take the drug should contact a doctor immediately if they have
thoughts of suicide, or worsening anxiety or depression, the agency
Aptiom is marketed by Sunovion Pharmaceuticals, based in
To learn more about epilepsy, visit the U.S.
Disease Control and Prevention.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.